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Purpose: Analysis of mutant mouse strains and linkage analysis with human families have both demonstrated that
mutations influencing the podosomal adaptor protein SH3 and PX domains 2B (SH3PXD2B) can result in a congenital
form of glaucoma. Here, we use immunohistochemistry to describe localization of the SH3PXD2B protein throughout
the adult human eye and test whether sequence variants in SH3PXD2B occur in multiple other forms of glaucoma.
Methods: In immunohistochemical experiments, cryosections of human donor eyes were evaluated for SH3PXD2B
immunoreactivity with a polyclonal antibody. In genetic experiments, exon sequences of SH3PXD2B from patients with
primary congenital glaucoma (n=21), Axenfeld-Rieger syndrome (n=30), and primary open angle glaucoma (n=127) were
compared to control subjects (n=89). The frequency of non-synonymous SH3PXD2B coding sequence variants were
compared between patient cohorts and controls using Fisher’s exact test.
Results: Varying intensities of SH3PXD2B immunoreactivity were detected in almost all ocular tissues. Among tissues
important to glaucoma, immunoreactivity was detected in the drainage structures of the iridocorneal angle, ciliary body,
and retinal ganglion cells. Intense immunoreactivity was present in photoreceptor inner segments. From DNA analysis,
a total of 11 non-synonymous variants were detected. By Fisher’s Exact test, there was not a significant skew in the overall
frequency of these changes in any patient cohort versus controls (p-value >0.05). Each cohort contained unique variants
not detected in other cohorts or patients.
Conclusions: SH3PXD2B is widely distributed in the adult human eye, including several tissues important to glaucoma
pathogenesis. Analysis of DNA variants in three forms of glaucoma detected multiple variants unique to each patient
cohort. While statistical analysis failed to support a pathogenic role for these variants, some of them may be rare disease-
causing variants whose biologic significance warrants investigation in follow up replication studies and functional assays.
The  glaucomas  are  a  leading  cause  of  blindness
worldwide  [1].  All  forms  of  glaucoma  ultimately  share  a
clinically  recognizable  form  of  progressive  optic  nerve
degeneration,  with  several  additional  pathologic  features
often present in distinct forms of the disease [2]. There is a
significant genetic contribution to the pathogenesis of most
forms of glaucoma and while several loci associated with
glaucoma  have  been  mapped  [3],  known  mutations  only
account for a small fraction of disease. Mutations in myocilin
and  optineurin  are  responsible  for  approximately  5%  of
primary open angle glaucoma (POAG) [4]. WD repeat domain
36 (WDR36) [5], neurotrophin 4 (NTF4) [6], ankyrin repeat
and  SOCS  box-containing  10  (ASB10)  [7],  and  TANK-
binding kinase 1 (TBK1) [8] are other genes that have also
been  reported  to  be  glaucoma-causing  genes,  but  are
controversial  or  have  not  yet  been  widely  replicated.
Similarly, genes have been discovered that cause primary
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congenital  glaucoma  (PCG),  cytochrome  P450,  family  1,
subfamily  B,  polypeptide  1  (CYP1B1)  [9]  and  latent
transforming growth factor beta binding protein 1 (LTBP2)
[10],  and  Axenfeld-Rieger  syndrome,  paired-like
homeodomain  2  (PITX2)  [11]  and  forkhead  box  C1
(FOXC1) [12,13]. Mutations in CYP1B1 are responsible for
10%–15% of simplex PCG cases [14-16], while mutations in
LTBP2  have  only  been  reported  in  PCG  families  from
Pakistan. It has been estimated that mutations in PITX2 and
FOXC1 are associated with 25%–30% of cases of Axenfeld-
Rieger syndrome in the United States [17], although these
numbers  vary  significantly  between  patient  populations.
Nonetheless,  these  data  indicate  that  many  more  disease-
causing  genes  for  these  conditions  have  not  yet  been
identified.  Recent  genome-wide  association  studies  of
primary open angle glaucoma have begun to identify genetic
factors that each contribute small risk for disease, including
caveolin 1 and 2 (CAV1/CAV2) [18] cyclin-dependent kinase
inhibitor  2B  antisense  RNA  1  (CDKN2B-AS1)  [19],  and
transmembrane and coiled-coil domains 1 (TMCO1) [19].
Risk alleles from these genes (and others) may combine to
lead to the development of some cases of glaucoma. Many
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705more of these risk alleles are likely to be discovered by larger
glaucoma genome-wide association study (GWAS) that are
currently underway.
Another  approach  to  discover  glaucoma  genes  is  by
studying  the  eyes  of  inbred  mice.  Recently,  these
investigations  identified  the  SH3  and  PX  domains  2B
(SH3PXD2B)  gene  as  a  potential  glaucoma-causing  gene
[20-22]. The nee strain of mice is a spontaneously arising
mutant that exhibits several glaucomatous defects, including
developmental  malformations  of  the  iridocorneal  angle,
elevated intraocular pressure, and optic nerve degeneration
[22]. We have recently identified the genetic basis of the nee
phenotype as a 1-bp Sh3pxd2b deletion that is predicted to
result  in  a  frame-shift  and  premature  stop  codon  [21].
Independently, Iqbal et al. [20] used linkage analysis and
characterization of a mouse mutation generated via gene-trap
to  link  SH3PXD2B  with  Frank-Ter  Haar  syndrome,  a
condition often involving congenital glaucoma [23,24]. Thus,
two independent lines of investigation have suggested that
severe  loss-of-function  mutations  in  SH3PXD2B  could
contribute to developmental forms of glaucoma. It remains
unknown  what  role,  if  any,  that  hypomorphic  alleles  of
SH3PXD2B might have.
We  have  tested  the  role  of  SH3PXD2B  in  glaucoma
pathogenesis. The Sh3pxd2b mutant mice have a homozygous
1  base  pair  deletion  in  the  Sh3pxd2b  gene  and  develop
congenital glaucoma with features similar to Axenfeld-Rieger
syndrome.  The  mice  have  congenital  craniofacial
abnormalities and peripheral anterior synechiae that mimic
the maxillary hypoplasia and iridocorneal angle abnormalities
that characterize Axenfeld-Rieger syndrome [21,22]. As a
result, we have tested the role of SH3PXD2B in Axenfeld-
Rieger syndrome by testing a cohort of patients for disease-
causing mutations. Given the role of SH3PXD2B in syndromic
congentital  glaucoma  associated  with  Frank-Ter  Haar
syndrome and the early onset glaucoma phenotype in the
Sh3pxd2b mutant mice, we also tested a cohort of primary
congenital glaucoma patients for disease-causing mutations
in SH3PXD2B. We similarly tested a cohort of adult-onset
primary open angle glaucoma (POAG) patients to determine
if variants in SH3PXD2B have a role in the pathogenesis of
this  more  common  form  of  glaucoma.  We  also  report
localization of SH3PXD2B protein throughout the normal
human  eye  using  immunohistochemistry.  The  results
demonstrate that SH3PXD2B is broadly expressed in many
ocular  tissues  important  to  glaucoma  and  that  the
SH3PXD2B gene harbors rare variants that may be important
in the pathophysiology of glaucoma.
METHODS
Immunohistochemistry:  Human  donor  eyes  were  obtained
from the Iowa Lions Eye Bank (Iowa City, IA) following
informed  consent  from  the  donors’  families.  The  average
death-to-preservation time for the eyes used in this study was
5.75  h  (range  3.75  to  8.1  h).  Immunohistochemistry  was
performed on tissue from two normal eyes of donors with ages
ranging  from  61  to  88  years.  Eyes  were  processed
immediately on receipt. Lenses were removed, and tissues
from the anterior and posterior poles were punched using
disposable  trephines,  and  punches  were  fixed  with  4%
paraformaldehyde in phosphate buffered saline (PBS) for 2 h.
The  removed  lenses  were  fixed  separately  with  a  similar
approach.  After  fixation,  tissues  were  rinsed  with  PBS.
Tissues  were  cryopreserved  with  sucrose  gradient  and
embedded  in  Optimal  Cutting  Temperature  embedding
medium  (Tissue-Tek  O.C.T.  Compound;  Sakura  Finetek,
Torrance, CA) [25]. Anterior and posterior punches were cut
at  6–8  µm  thickness.  The  lenses  were  cut  at  18–20  µm
thickness.  Sections  were  air  dried  for  30  min  at  room
temperature, rehydrated in PBS for 5 min, and blocked with
10% goat serum, 3% BSA (BSA) in PBS for 1 h at room
temperature. Sections were then incubated overnight at 4 °C
with a rabbit anti-human SH3PXD2B polyclonal antibody
(Millipore, Temecula, CA) diluted at 1:50 in 1% goat serum,
1% BSA in PBS. Adjacent sections incubated without the
primary  antibody  were  used  as  negative  controls.  After
washes with 0.1% Tween-20 in PBS (3×10 min), sections
were incubated with Alexa488-conjugated goat anti-rabbit
antibody (Invitrogen, Carlsbad, CA) diluted at 1:200 in 1%
goat serum, 1% BSA in PBS for 1 h at room temperature.
Following washes, sections were incubated with To-Pro-3
(1:1000 dilution in PBS; Invitrogen, Carlsbad, CA) for 15 min
at  room  temperature  to  stain  nuclei.  Sections  were  then
washed  several  times  in  PBS,  mounted  (ProLong  Gold;
Invitrogen,  Carlsbad,  CA)  and  imaged  with  a  confocal
microscope (Zeiss LCM 510; Carl Zeiss MicroImaging, Inc.,
Thornwood,  NY).  Two  eyes  were  examined  and
immunolabeling was repeated twice for each eye.
Human  subjects:  All  subjects  enrolled  in  the  study  gave
informed  consent  and  the  research  was  conducted  with
approval of the University of Iowa’s Internal Review Board.
Twenty-one patients with primary congenital glaucoma had
typical features of disease including a diagnosis before 3 years
of  age,  open  angles  on  gonioscopy,  elevated  intraocular
pressure, buphthalmos, and Haab striae. Thirty patients with
Axenfeld-Rieger syndrome had characteristic features of the
condition  including  posterior  embrotoxon,  iris  processes,
correctopia, polycoria, redundant periumbilical tissue, and
dental abnormalities. One hundred and twenty seven patients
with POAG had excavation of their optic nerve head with
resultant glaucomatous visual field loss in at least one eye.
Glaucomatous optic nerves had cup-to-disc ratios of greater
than 0.7 with thinning of the neural rim, asymmetry of the
optic  nerve  cup-to-disc  ratio  of  >0.2,  or  photographic
documentation of progressive loss of the neural rim. Patients
were 40 years of age or older at diagnosis and had open
iridocorneal angles on gonioscopy (angle greater than Shaffer
grade II). Patients were also required to have an IOP of greater
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subjects were a minimum of 50 years old and were examined
and judged to have normal optic nerve head appearance and
IOP  ≤21  mmHg  by  board-certified  ophthalmologists.  All
study subjects were examined by clinicians at the University
of Iowa Hospitals and Clinics and ascertained in Iowa.
Genetic  analysis:  DNA  samples  were  prepared  from
peripheral blood samples extracted from patients in the clinic
by standard procedures. The coding region of SH3PXD2B
(NM_001017995)  was  PCR  amplified  using  overlapping
primer pairs in standard PCR reactions (Table 1). This assay
encompass 97% of the coding sequence of the longest isoform
of SH3PXD2B . Amplified DNA was scanned for mutations
with  a  combination  of  single  strand  conformation
polymorphism  (SSCP)  analysis  and  bi-directional  DNA
sequencing with an Applied Biosystems (ABI) model 3730
automated  sequencer  as  previously  described  [8].  Those
mutations  that  result  in  amino  acid  substitutions  were
evaluated  using  the  blosum62  matrix,  which  provides  an
integer score for these substitutions that ranges from −4 to +3.
More positive blosum62 scores indicate conservative amino
acid changes that are less likely to be pathogenic, while more
negative scores indicate less conservative substitutions that
are more likely to cause disease [26].
RESULTS
SH3PXD2B  expression  in  human  eyes:  Based  on  several
published microarray studies [27-33], in situ hybridization
data from mice [20], and limited experiments with ocular
tissues dissected from mice [22], SH3PXD2B is predicted to
have  a  broad  ocular  expression.  However,  the
immunolocalization of SH3PXD2B protein throughout the
eye has not previously been examined. To characterize the
distribution  of  SH3PXD2B  protein  in  adult  human  eyes,
immunofluorescent  labeling  was  performed  using  a
polyclonal  antibody  against  human  SH3PXD2B  on
cryosections of healthy human donors (Figure 1). Presence of
SH3PXD2B immunoreactivity was demonstrated on multiple
tissues  in  the  eye,  including  the  cornea,  iris,  trabecular
meshwork, ciliary body, retina, and the lens. In the cornea,
relatively  strong  immunostaining  was  observed  in  the
cytoplasm of corneal epithelium (Figure 1A) and endothelium
(Figure 1B), while there was definite but weak labeling of the
keratocytes in the corneal stroma (Figure 1A,B). Similarly,
wide  distribution  of  SH3PXD2B  was  also  found  in  the
cytoplasm of all cell types of the iris and trabecular meshwork
(Figure  1C,D).  In  the  ciliary  body  (Figure  1I,J),  strong
labeling was detected in the non pigmented epithelium of the
ciliary process and the ciliary muscle. Immunoreactivity of
the  pigmented  epithelium  of  the  ciliary  process  was  less
intense. In the retina (Figure 1K), the immunoreactivity was
detected in most layers including the retinal ganglion layer,
the main cell type affected during glaucoma. Interestingly, the
strongest  labeling  of  the  retina  was  detected  in  the  inner
segment. Definite, but weak labeling of the lens epithelium
and lens cortex were also observed (Figure 1L). No signal was
detected in negative controls stained only with the secondary
antibody  (Figure  1E-H,M-P).  These  results  demonstrate  a
broad distribution of SH3PXD2B in human eyes and support
a possible role of SH3PXD2B in the pathogenesis of a variety
of ocular diseases.
TABLE 1. THE CODING REGION OF SH3PXD2B WAS PCR AMPLIFIED USING OVERLAPPING PRIMER PAIRS.
Exon Forward primer Reverse primer
2 GTCCCAGAGATTGGGAGACC GAATGTAAGTCCAATTAAACTCTTTCC
3 AAATGTCCTAGATGATGTTTAGTGC CAAGGGCTCTGGGAACTGTA
4 GGCACCACTCAGACCTACCC GCACAAATTTTTATTGTTGAGCAT
5 CAAACAATTATCTTGCCTCAGC TGCTTTACTTGGGGGTGGC
6 AATACATGGCAAGTCTGACTCG GTTTGCCGAAAACTGAACGA
7 TGACTCCTGCTCTTTCATGC GAGTTTCCAAATGTTTCATGTCC
8 TTCACTGGTACAGTGGCTGAAT GCAACCCAGTATAGGCGATG
9 AAGGGCATCACGGGGATT GTGAGGCCAGAGTCCCTGT
10A TGTGATTCCCAGTAGGAGCA TGCTGAGCAGCTCCTTCT
10B GTGCCCTTGACTTGGATGG GATGTGAGACGCCTTGAGC
11 CCCAGCTCAGGAATCTCATC TGTGTGAGGGGCTAGTGGAC
12 GACACAGGGTCGCAGGAGT GGGGAGAAGTAGGAGGTGATG
13A CCAAACCATTCCATCTGCTG GGAGCTGGGTCACCTCGT
13B AGGACTCTTTGTATGTGGCCGTG AAGCCAGCAAGGACCAGCGGG
13C AACGCGTCGAGACCCAAC GGGGTCTGAGATCTCCTCGTA
13D ATGTCCTGAGGAAGGCATC TTTTGTCAGGTTTGGGCTCT
13E GTGATTTTGCCGATGATGC TCTGGACTTCAAGAAGGGATTC
13F GCCCATCTCCAAATCCAAAA CCCTCCCCATCCAACAAG
13G GACCAAGTCGACATCTGCAA GCACGCTCTTAGACACAGGAT
13H GGGCAAACAGGATGGTCT GAGAAAAGGTTTGGCTTTTGG
13I ACAGTGTGAAGGCCACGAAA CCTGGAAGCTGCTGGTGT
Molecular Vision 2012; 18:705-713 <http://www.molvis.org/molvis/v18/a75> © 2012 Molecular Vision
707DNA variations in SH3PXD2B: A total of 24 unique variations
were  detected  in  the  SH3PXD2B  gene  including  11  non-
synonymous  coding  sequence  variations,  5  synonymous
coding sequence variations, and 8 intron variations (Table 2).
The SH3PXD2B protein has one segment with homology
to a phosphoinositide binding Phox (PX) domain that extends
from amino acid 7–125 and four src homology (SH3) domains
that span amino acids 156–207, 225–277, 373–422, and 855–
909 [34]. Non-synonymous mutations in SH3PXD2B, were
Figure 1. Localization of SH3PXD2B in human eyes. Immunohistochemistry labeling of SH3PXD2B on human eyes reveals localization of
SH3PXD2B in most ocular cell types. (A-D, I-L) Cryosections were labeled with an anti-SH3PXD2B antibody (Green) and To-Pro-3, a
nuclear counterstain (blue). (E-H, M-P) Negative controls omitting the primary antibody were performed on adjacent sections. (A-B, E-F)
Cornea. (C, G) Iris. (D, H) Trabecular meshwork. (I, M) Ciliary processes. (J, N) Ciliary muscles. (K, O) Retina. (L, P) Lens. The orange-
yellow color in K and O represents lipofuscin autofluorescence in the retinal pigment epithelium. cep, corneal epithelium; cen, corneal
endothelium; ist, iris stroma; ipe, iris pigment epithelium; tm, trabecular meshwork; sc, Schlemm’s canal; gcl, ganglion cell layer; inl, inner
nuclear layer; onl, outer nuclear layer; is, inner segment; os, outer segment. Scale bar=50 µm.
Molecular Vision 2012; 18:705-713 <http://www.molvis.org/molvis/v18/a75> © 2012 Molecular Vision
708not clustered within any particular functional domains of the
gene. None of the detected non-synonymous codon variations
(Table 2) were located in the PX domain, while one variation
(Gly245Arg)  was  located  in  the  second  SH3  domain  and
another variation (Glu396Lys) was located within the third
SH3 domain.
The detected SH3PXD2B variants were analyzed using
the blosum62 matrix. Some amino acid substitutions are more
deleterious to protein function than others and have more
negative blosum62 scores. Each of the 11 non-synonymous
coding sequence variants that we detected in SH3PXD2B was
evaluated with the blosum62 matrix to estimate their potential
effects on protein function (Table 2). Five of the 11 variants
(Gly245Arg,  Gly481Arg,  Pro571Leu,  Pro826Leu,
Gly833Glu) had blosum62 scores of −2 or −3 which suggests
that they may be harmful to protein function. It is notable that
of these 11 variants, only one (Gly245Arg) is located within
a known functional domain and has a negative blosom62
score.
When  the  frequencies  of  non-synonymous  coding
sequence  variations  were  compared  between  the  primary
congenital  glaucoma  patients  and  control  subjects,  no
significant difference was detected (p-value >0.99). Similar
results were obtained for Axenfeld-Rieger syndrome (p-value
>0.99) and POAG (p-value >0.76).
DISCUSSION
Animal models provide key resources for investigating the
biologic  pathways  that  lead  from  a  gene  defect  to  the
development  of  disease.  Studies  of  animal  models  have
already facilitated the development of powerful diagnostic
tests and effective therapeutic strategies, such as gene therapy
for Leber Congenital Amaurosis caused by defects in the
retinal pigment epithelium-specific protein 65kDa (RPE65)
gene [35-37].
However, with respect to glaucoma, there are currently
few  mouse  models  that  recapitulate  the  genotype  and
phenotype of human disease [38].
Multiple lines of evidence suggest that SH3PXD2B is
relevant to human glaucoma. Loss of function mutations in
SH3PXD2B  have  been  linked  to  the  form  of  congenital
glaucoma occurring in Frank-Ter Haar syndrome [20] and
nee mutant mice [21,39]. SH3PXD2B is an adaptor protein
that has a vital role in the formation and function of podosome-
like adhesions and interacts with other molecules that are
important in maintenance of the extracellular matrix [21,39,
TABLE 2. SH3PXD2B VARIANTS.
Variations BLOSUM62
matrix score
Located within
protein domain
Primary congenital
glaucoma n=21
Axenfeld-Reiger
syndrome n=30
POAG
n=127
Normal control
subjects n=89
Non-synonymous coding sequence variations
Gly245Arg −2 SH3 #2 0 0 1 0
Pro295Gln −1 - 0 0 2 2
Arg356Gln 1 - 0 0 1 0
Glu396Lys 1 SH3 #2 1 0 0 0
Ala431Thr 0 - 0 1 0 0
Gly481Arg −2 - 0 0 1 0
Pro571Leu −3 - 0 1 0 0
Pro826Leu −3 - 0 0 0 1
Ile832Val 3 - 0 0 1 0
Gly833Glu −2 - 0 0 0 1
Glu834Lys 1 - 0 0 0 1
Total 1 2 6 5
Synonymous coding sequence variations
Ala195Ala - - 0 0 1 0
Ser174Ser - - 0 0 3 1
Ser35Ser - - 16 22 90 61
Asp385Asp - - 1 0 0 1
Thr428Thr - - 1 0 0 1
Intravening sequence variations
IVS3–28 a>g - - 3 1 9 4
IVS7–11 c>t - - 8 13 63 59
IVS7+50 t>c - - 0 0 3 1
IVS10–27 a>g - - 5 0 6 9
IVS11–9 t>c - - 1 1 0 0
IVS11–8 c>t - - 1 1 0 0
IVS11–7 g>t - - 0 0 2 1
IVS12–43 c>t - - 0 0 2 3
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70940]. Podosomes have previously been observed in cells of the
trabecular meshwork and are likely to regulate localization of
matrix  metalloproteinases  capable  of  influencing  outflow
facility [41,42]. As such, it is plausible that SH3PXD2B may
influence trabecular meshwork structure and function, facility
of outflow, and intraocular pressure. Finally, we have shown
with immunohistochemistry that SH3PXD2B is expressed in
tissues of the human eye that are important in the glaucoma
including the trabecular meshwork, ciliary body, and retina.
Prior studies of SH3PXD2B showed that loss of function
mutations are associated with a congenital form of glaucoma
as part of Frank-Ter Haar syndrome, suggesting that we might
find  similar  defects  in  a  cohort  of  primary  congenital
glaucoma patients and possibly hypomorphic alleles in other
forms of human glaucoma. Based on these observations, we
set out to test cohorts of glaucoma patients for mutations in
the SH3PXD2B to determine if the same defects that cause
glaucoma in the Sh3pxd2b mutant mice are responsible for
human disease.
We  detected  14  instances  of  11  non-synonymous
SH3PXD2B  coding  sequence  variations  in  our  cohorts  of
primary  congenital  glaucoma,  Axenfeld-Rieger  syndrome,
primary open angle glaucoma, and control subjects (Table 2).
Rare SH3PXD2B variants were detected in each cohort that
were absent from the normal control cohort. One (4.8%) of 21
primary congenital glaucoma subjects carried a Glu396Lys
mutation that is located in the third SH3 domain and has a
relatively benign blosum62 score of “1.” Two (6.7%) of the
30 Axenfeld-Rieger syndrome patients carried SH3PXD2B
variations,  one  patient  with  Ala431Thr  and  another  with
Pro571Leu. Neither of these variants alter known functional
domains of SH3PXD2B, however, one variant, Pro571Leu,
has a negative blosum62 score of “-3” implying that it may
have  some  effect  on  the  encoded  SH3PXD2B  protein.
SH3PXD2B  variants  were  detected  in  six  (4.7%)  of  127
POAG  patients,  including  4  variants  (Gly245Arg,
Arg356Gln,  Gly481Arg,  and  Ile832Val)  that  were  absent
from  normal  control  subjects.  Two  of  these  variants
(Gly245Arg and Gly481Arg) have blosum62 scores of −2 and
Gly245Arg is also located within the second SH3 domain of
SH3PXD2B.  Finally,  five  (5.6%)  of  89  normal  control
subjects  were  found  to  carry  SH3PXD2B  mutations  with
blosum62 scores that range from −3 to +1 and none were
located in known functional domains. Of note, two of these
variants were unique to the cohort of normal control subjects.
These data demonstrate that SH3PXD2B variants are not a
common cause of primary congenital glaucoma, Axenfeld-
Rieger syndrome, or POAG. However, it is certainly possible
that our research failed to identify disease-causing mutations
in SH3PXD2B that would be detectable with the power of a
study with larger cohorts of patients and controls.
Among the variants identified, Gly245Arg stands out as
a  possible  rare  disease-causing  variant.  In  addition  to  a
pathogenic prediction based on blosum62 score [26,43], the
change  is  also  predicted  to  be  deleterious  by  multiple
additional  algorithms  (data  not  shown),  including  Sorting
Tolerant  From  Intolerant  (SIFT)  [44],  Polymorphism
Phenotyping (PolyPhen) [45], and Align Grantham Variation
Grantham Deviation (A-GVGD) [46]. This is significant as it
has  been  previously  suggested  that  there  is  improved
predictive  value  when  all  four  of  these  methods  are  in
agreement [47]. There is also biologic evidence suggesting
pathogenicity. SH3 domains typically consist of 5 or 6 beta-
strands  arranged  as  two  anti-parallel  beta  sheets  that
essentially form a barrel-like structure mediating protein–
protein interactions [48]. The Gly245Arg substitution affects
a highly conserved Gly residue within a linker region between
beta-strands contributing to a type II beta-turn. Based on an
analysis  of  266  nonredundant  sequences  encoding  SH3
domains, this Gly is the fifth most highly conserved residue
of  the  60  constituting  a  SH3  domain  [48].  The  residue
conservation at this position is thought to be explained by a
requirement for the backbone to adopt a left-handed helical
conformation for which Gly is strongly favored, both in SH3
domains [48] and in type II beta-turns in general [49]. Though
speculative, it is plausible that the Gly245Arg substitution
could disrupt folding and ability of the second SH3 domain to
participate in protein–protein interactions, thus resulting in a
hypomorphic or dominant negative mutation. However, given
the  rarity  of  Gly245Arg  variant,  additional  functional
experiments would be required to test this hypothesis directly.
One other SH3PXD2B variation (Pro826Leu) was also
associated  with  a  blosum62  score  of  −3  that  suggests
pathogenicity.  However,  the  proline  amino  acid  in
SH3PXD2B protein that is altered by this mutation is not
strongly conserved across species, nor does A-GVGD suggest
that this variation is likely deleterious. Lastly, the Pro826Leu
variant has been detected in the exome sequencing project at
a frequency of approximately 1% which suggests that it is too
common  to  be  a  glaucoma-causing  mutation.  Despite  the
suggestive blosum62 score, the sum of the available data does
not  support  a  disease-causing  role  for  the  Pro826Leu
variation.
In  summary,  we  previously  showed  that  mutation  of
Sh3pxd2b generates a severe, congenital form of glaucoma in
mice  [21,22],  which  suggests  that  the  human  ortholog
(SH3PXD2B)  and  interacting  proteins  are  also  good
candidates for causing disease in humans. We tested cohorts
of  patients  with  primary  congenital  glaucoma,  Axenfeld-
Rieger syndrome, and POAG for SH3PXD2B defects and
found several rare variants. While analyses of these data were
unable  to  establish  a  statistically  significant  link  between
SH3PXD2B and these eye conditions, we have demonstrated
that SH3PXD2B is localized to multiple tissues relevant to
glaucoma and identified changes warranting future functional
studies.
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